Scinovex
review Open AccessTop 1% cited

Practice guideline update summary: Mild cognitive impairment [RETIRED]

Neurology · 2017 · Vol. 90(3) · pp. 126–135
Ronald C. PetersenOscar L. LópezMelissa J. ArmstrongThomas S.D. GetchiusMary GanguliDavid GlossGary GronsethDaniel MarsonTamara PringsheimGregory S. DayMark A. SagerJames C. StevensAlexander Rae‐Grant

Abstract

Clinicians should assess for MCI with validated tools in appropriate scenarios (Level B). Clinicians should evaluate patients with MCI for modifiable risk factors, assess for functional impairment, and assess for and treat behavioral/neuropsychiatric symptoms (Level B). Clinicians should monitor cognitive status of patients with MCI over time (Level B). Cognitively impairing medications should be discontinued where possible and behavioral symptoms treated (Level B). Clinicians may choose not to offer cholinesterase inhibitors (Level B); if offering, they must first discuss lack of evidence (Level A). Clinicians should recommend regular exercise (Level B). Clinicians may recommend cognitive training (Level C). Clinicians should discuss diagnosis, prognosis, long-term planning, and the lack of effective medicine options (Level B), and may discuss biomarker research with patients with MCI and families (Level C).

Dementia and Cognitive Impairment ResearchFrailty in Older AdultsNeurological Disorders and TreatmentsMedicineGuidelineDementiaCognitionNeurologyMEDLINECognitive impairmentIncidence (geometry)DonepezilPhysical therapy

MeSH terms

Delphi TechniqueHumansCognitive Dysfunction
Citations
2,095
FWCI
76.94
field-weighted impact
References
49
Percentile
100%
vs. same field & year
Citations per year
References
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Practice guideline update summary: Mild cognitive impairment [RETIRED] · Scinovex